Bloomberg: Strides Aroclab ponders sale of injectables operation

Sources tell Bloomberg that Bangalore, India-based Strides Arcolab, which supplies injectable drugs to Pfizer ($PFE), GlaxoSmithKline ($GSK) and Novartis ($NVS), is evaluating a sale of its injectable-drugs division, Agila Specialties. The sources put an $800 million value on the unit but analysts say it might be worth twice that based on what other drug company deals have garnered lately. Bloomberg says ​from 2008 to 2010 Agila had the highest number of FDA injectable-medicine approvals with 32, compared with 23 at rival Hospira ($HSP). It has at least 8 manufacturing facilities in India, Brazil and Poland, having picked up a new injectables plant in India in April. Story | More

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.